Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HUMEGON vs A.P.L.
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
HUMEGON (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from the urine of postmenopausal women. It acts by stimulating ovarian follicular growth and maturation in women and spermatogenesis in men via binding to FSH and LH receptors on target cells.
A. P. L. (Chorionic Gonadotropin) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads to stimulate testosterone production in males and ovulation in females.
Induction of ovulation in women with oligomenorrhea or anovulation not due to primary ovarian failure,Stimulation of multiple follicle development in ovulatory women participating in assisted reproductive technology (ART) programs,Induction of spermatogenesis in men with hypogonadotropic hypogonadism (in combination with h CG)
Induction of ovulation in anovulatory infertile women,Treatment of hypogonadism and cryptorchidism in males,Off-label: Assisted reproductive technology (ART) protocols
75 to 150 IU subcutaneously or intramuscularly once daily for 7 to 12 days, adjusted based on follicular response.
500-1000 mg every 4-6 hours, not to exceed 3000 mg/day in adults.
Terminal half-life approximately 23-24 hours (range 20-30 h) for FSH and LH activity; clinical significance: once-daily dosing achieves steady-state in 4-5 half-lives (approx. 5 days).
Terminal elimination half-life: 2.5–3.5 hours (elimination phase); clinical context: requires repeated dosing for sustained effect.
The metabolic pathway of menotropins is not fully characterized; however, it is likely degraded via proteolysis into smaller peptides and amino acids in the liver and kidneys.
Primarily via glucuronidation (60%) and sulfation (35%) in the liver, with a minor portion (5%) via CYP2E1 oxidation to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is normally detoxified by glutathione.
Primarily renal (90-95% as intact hormone and metabolites); biliary/fecal excretion minor (<5%).
Renal: 10% unchanged; hepatic metabolism to inactive metabolites excreted in urine and feces (90% combined).
Approximately 30-40% bound to serum albumin; no specific binding proteins identified.
80–90% bound to sex hormone-binding globulin (SHBG) and albumin.
Approximately 0.3-0.5 L/kg (total body water); indicates distribution primarily into extracellular fluid.
0.5–0.9 L/kg, indicating moderate tissue distribution (primarily gonads and liver).
IM/SC: Approximately 80-90% absolute bioavailability (due to first-pass hepatic metabolism with oral route being ineffective).
IM: 100%; Subcutaneous: ~80% (relative to IM); Oral: <5% (not clinically used).
No specific dose adjustment guidelines; use caution in severe renal impairment.
No specific adjustment required for mild to moderate renal impairment. In severe renal impairment (Cr Cl < 10 m L/min), extend dosing interval to every 8 hours.
No specific dose adjustment guidelines; use caution in severe hepatic impairment.
Caution in severe hepatic impairment; consider dose reduction or extended interval. Avoid use in active liver disease.
Not indicated for use in pediatric patients.
Weight-based: 10-15 mg/kg every 4-6 hours, not to exceed 5 doses per day or 75 mg/kg/day.
Not indicated for use in geriatric patients.
No specific dose adjustment, but consider renal and hepatic function and avoid exceeding 3000 mg/day.
HUMEGON should only be used by physicians who are experienced in infertility treatment and familiar with the potential risks. The drug has been associated with serious pulmonary and vascular events, including thromboembolism, ovarian hyperstimulation syndrome (OHSS), and multiple pregnancies. Female patients should be advised of the risk of OHSS and multiple gestations.
No black box warning.
Risk of Ovarian Hyperstimulation Syndrome (OHSS): may progress to severe form with ascites, pleural effusion, oliguria, and thromboembolic events.,Thromboembolic events: increased risk especially in patients with predisposing factors.,Ovarian torsion: reported in post-treatment period.,Multiple pregnancies: high incidence, especially with higher doses.,Ovarian enlargement: may be asymptomatic or cause abdominal pain.,Ectopic pregnancy: increased risk in patients with tubal disease.,Congenital malformations: incidence may be slightly higher than spontaneous pregnancies.,Monitoring: requires ultrasound and estradiol levels to minimize risks.
May cause fluid retention, ovarian hyperstimulation syndrome (OHSS) in females,Increased risk of thromboembolic events,Precocious puberty in males,Not for use in prepubertal children unless for cryptorchidism
High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Pituitary tumor,Abnormal uterine bleeding of undetermined origin,Ovarian cyst or enlargement not due to polycystic ovary syndrome (PCOS),Sex hormone-dependent tumors (e.g., breast, uterus, ovary, prostate),Pregnancy,Hypersensitivity to menotropins or any component
Hypersensitivity to chorionic gonadotropin or any component,Precocious puberty (in males),Prostatic carcinoma or other androgen-dependent neoplasms,Ovarian cyst or enlargement not due to polycystic ovary syndrome
No specific food interactions documented. Maintain a balanced diet; no restrictions necessary.
No known food interactions. Avoid alcohol during treatment.
HUMEGON (menotropins) is not indicated for use during pregnancy. Human menopausal gonadotropin is used for ovulation induction and may result in multiple gestations. No teratogenic effects have been reported from inadvertent exposure during early pregnancy, but fetal risks include increased incidence of multiple births and associated prematurity, low birth weight, and perinatal morbidity. Avoid use during pregnancy.
A. P. L. (chorionic gonadotropin) is not expected to increase the risk of congenital anomalies when used in early pregnancy. However, use in the first trimester is generally avoided unless indicated for specific conditions. Data are limited; no increased fetal risk reported in inadvertent exposures. Second and third trimester use is not associated with teratogenicity but may increase risk of multiple gestation (if used for ovulation induction).
It is not known whether menotropins are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when administered to a nursing woman. No M/P ratio is available.
Chorionic gonadotropin is not detected in breast milk following maternal administration. M/P ratio not established. Considered compatible with breastfeeding; no adverse effects on infant reported. Use with caution if high doses are administered.
HUMEGON is contraindicated during pregnancy. No dosing adjustments in pregnancy are applicable as it is not used during pregnancy.
No pharmacokinetic studies in pregnancy. Dose adjustments are not typically required during pregnancy for standard indications. For ovulation induction, dosing is based on follicular development. In first trimester for luteal support, standard doses are used. No evidence of altered clearance or need for dose changes due to pregnancy.
Humegon (menotropins) contains FSH and LH activity. Monitor estradiol levels and follicular growth via ultrasound to adjust dosing and minimize OHSS risk. Administer IM or SC; reconstitute with provided diluent and use immediately. Avoid in primary ovarian failure. Combine with h CG for final oocyte maturation.
A. P. L. (chorionic gonadotropin) is used to trigger ovulation in assisted reproductive technology. Administer when follicles are mature (≥18 mm). Risk of ovarian hyperstimulation syndrome (OHSS) increases with higher doses. Monitor for abdominal pain, distension, and weight gain. Use caution in patients with prior thromboembolism.
Inject exactly as prescribed; do not miss doses.,Report abdominal pain, bloating, nausea, or rapid weight gain immediately (OHSS signs).,Multiple pregnancy is possible; discuss risks.,Store unopened vials in refrigerator; use reconstituted solution promptly.,Avoid alcohol and smoking during treatment.,Inform doctor of all medications, including herbal supplements.
This medication is given as an injection exactly as prescribed to trigger ovulation.,A single dose is usually sufficient; follow your doctor's timing instructions closely.,Common side effects include headache, fatigue, and injection site reactions.,Seek immediate medical help if you experience severe pelvic pain, nausea, vomiting, or sudden weight gain (signs of OHSS).,Report symptoms of blood clots: leg pain, chest pain, or shortness of breath.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HUMEGON vs A.P.L., answered by our medical review team.
HUMEGON is a Gonadotropin that works by HUMEGON (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from the urine of postmenopausal women. It acts by stimulating ovarian follicular growth and maturation in women and spermatogenesis in men via binding to FSH and LH receptors on target cells.. A.P.L. is a Gonadotropin that works by A. P. L. (Chorionic Gonadotropin) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads to stimulate testosterone production in males and ovulation in females.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HUMEGON and A.P.L. depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HUMEGON is: 75 to 150 IU subcutaneously or intramuscularly once daily for 7 to 12 days, adjusted based on follicular response.. The standard adult dose of A.P.L. is: 500-1000 mg every 4-6 hours, not to exceed 3000 mg/day in adults.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HUMEGON and A.P.L. in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HUMEGON is classified as Category C. HUMEGON (menotropins) is not indicated for use during pregnancy. Human menopausal gonadotropin is used for ovulation induction and may result in multiple gestations. No teratogenic. A.P.L. is classified as Category C. A.P.L. (chorionic gonadotropin) is not expected to increase the risk of congenital anomalies when used in early pregnancy. However, use in the first trimester is generally avoided . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.